Deutsche Bank Reiterates Buy on Valeant Pharmaceuticals, Raises PT to $64

by Emily Austin, Benzinga Staff Writer
July 18, 2011 9:26 AM | 17 seconds read |
Deutsche Bank reiterated its Buy rating on Valeant Pharmaceuticals VRX. At the same time, the rating agency raised its price target on the company's stock from $62 to $64. On Friday, VRX closed the day at $55. Its shares added 0.29% to their value in today's pre-market trading to stand around $55.16.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetReiterationAnalyst RatingsDeutsche BankHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!